Months after recovering from mild cases of COVID-19, people still have immune cells in their body pumping out antibodies against the virus that causes COVID-19, according to a study from researchers at Washington University School of Medicine in St. Louis. Such cells could persist for a lifetime, churning out antibodies all the while.
The findings, published May 24 in the journal Nature, suggest that mild cases of COVID-19 leave those infected with lasting antibody protection and that repeated bouts of illness are likely to be uncommon.
“Last fall, there were reports that antibodies wane quickly after infection with the virus that causes COVID-19, and mainstream media interpreted that to mean that immunity was not long-lived,” said senior author Ali Ellebedy, PhD, an associate professor of pathology & immunology, of medicine and of molecular microbiology. “But that’s a misinterpretation of the data. It’s normal for antibody levels to go down after acute infection, but they don’t go down to zero; they plateau. Here, we found antibody-producing cells in people 11 months after first symptoms. These cells will live and produce antibodies for the rest of people’s lives. That’s strong evidence for long-lasting immunity.”
Can you get the seasonal flu along with the raging coronavirus at the same time? That may be the question on everyone’s mind this pandemic pre-flu season. The following is what Johns Hopkins Medicine has to say on the subject.
Unfortunately, yes — and if you have the coronavirus and the flu at the same time, the resulting impact could be even more severe than having either infection alone. By this fall, some areas may have a test available that can look for both the coronavirus and flu viruses so you only need one test.
I have been writing this blog since March 2010. There are approximately 4000 posts in here. Without a doubt, one of the most incendiary topics in that entire time is … flu shots. I get one every year. My doctor tells me to. I listen to her and I got one on Friday. I think you should, too. In view of the pandemic it is even more important.
As the flu season approaches in the United States, health experts are warning that the addition of another respiratory illness on top of the ongoing COVID-19 pandemic could overburden the health care system, strain testing capacity, and increase the risk of catching both diseases at once, according to the University of California San Francisco.
In a bad flu season, which peaks from December to February, 40 million to 50 million Americans may catch the flu, with some 800,000 requiring hospitalization, according to Charles Chiu, MD, PhD, an infectious disease expert at UC San Francisco.
“So the worry is that with the onset of the flu season, you’re going to get peaks of flu and COVID-19 cases at the same time,” he said. “Even with a mild flu season, the convergence with a COVID surge could very rapidly overwhelm our hospital system.”
Unlike COVID-19, however, the flu is a familiar foe, and a safe and effective vaccine is available every year.
Collateral damage from the coronavirus continues to mount. Researchers have identified specific sub-populations of brain cells in the prefrontal cortex, a key part of the brain that regulates social behavior, that are required for normal sociability in adulthood and are profoundly vulnerable to juvenile social isolation in mice.
Loneliness is recognized as a serious threat to mental health. Even as our world becomes increasingly connected over digital platforms, young people in our society are feeling a growing sense of isolation. The COVID-19 pandemic, which forced many countries to implement social distancing and school closures, magnifies the need for understanding the mental health consequences of social isolation and loneliness. While research has shown that social isolation during childhood, in particular, is detrimental to adult brain function and behavior across mammalian species, the underlying neural circuit mechanisms have remained poorly understood.
Few people who have undergone nasopharyngeal swabs for coronavirus testing would describe it as a pleasant experience. The procedure involves sticking a long swab up the nose to collect a sample from the back of the nose and throat, which is then analyzed for SARS-CoV-2 RNA by the reverse-transcription polymerase chain reaction (RT-PCR). Now, researchers reporting in ACS Nano have developed a prototype device that non-invasively detected COVID-19 in the exhaled breath of infected patients.
In addition to being uncomfortable, the current gold standard for COVID-19 testing requires RT-PCR, a time-consuming laboratory procedure. Because of backlogs, obtaining a result can take several days. To reduce transmission and mortality rates, healthcare systems need quick, inexpensive and easy-to-use tests. Hossam Haick, Hu Liu, Yueyin Pan and colleagues wanted to develop a nanomaterial-based sensor that could detect COVID-19 in exhaled breath, similar to a breathalyzer test for alcohol intoxication. Previous studies have shown that viruses and the cells they infect emit volatile organic compounds (VOCs) that can be exhaled in the breath.
The researchers made an array of gold nanoparticles linked to molecules that are sensitive to various VOCs. When VOCs interact with the molecules on a nanoparticle, the electrical resistance changes. The researchers trained the sensor to detect COVID-19 by using machine learning to compare the pattern of electrical resistance signals obtained from the breath of 49 confirmed COVID-19 patients with those from 58 healthy controls and 33 non-COVID lung infection patients in Wuhan, China. Each study participant blew into the device for 2-3 seconds from a distance of 1–2 cm. Once machine learning identified a potential COVID-19 signature, the team tested the accuracy of the device on a subset of participants. In the test set, the device showed 76% accuracy in distinguishing COVID-19 cases from controls and 95% accuracy in discriminating COVID-19 cases from lung infections. The sensor could also distinguish, with 88% accuracy, between sick and recovered COVID-19 patients. Although the test needs to be validated in more patients, it could be useful for screening large populations to determine which individuals need further testing, the researchers say.
Respiratory droplets from a cough or sneeze travel farther and last longer in humid, cold climates than in hot, dry ones, according to a study on droplet physics by an international team of engineers. The researchers incorporated this understanding of the impact of environmental factors on droplet spread into a new mathematical model that can be used to predict the early spread of respiratory viruses including COVID-19, and the role of respiratory droplets in that spread.
The team developed this new model to better understand the role that droplet clouds play in the spread of respiratory viruses. Their model is the first to be based on a fundamental approach taken to study chemical reactions called collision rate theory, which looks at the interaction and collision rates of a droplet cloud exhaled by an infected person with healthy people. Their work connects population-scale human interaction with their micro-scale droplet physics results on how far and fast droplets spread, and how long they last.r
Their results were published June 30 in the journal Physics of Fluids.
“The basic fundamental form of a chemical reaction is two molecules are colliding. How frequently they’re colliding will give you how fast the reaction progresses,” said Abhishek Saha, a professor of mechanical engineering at the University of California San Diego, and one of the authors of the paper. “It’s exactly the same here; how frequently healthy people are coming in contact with an infected droplet cloud can be a measure of how fast the disease can spread.”
They found that, depending on weather conditions, some respiratory droplets travel between 8 feet and 13 feet away from their source before evaporating, without even accounting for wind. This means that without masks, six feet of social distance may not be enough to keep one person’s exhalated particles from reaching someone else.
“Droplet physics are significantly dependent on weather,” said Saha. “If you’re in a colder, humid climate, droplets from a sneeze or cough are going to last longer and spread farther than if you’re in a hot dry climate, where they’ll get evaporated faster. We incorporated these parameters into our model of infection spread; they aren’t included in existing models as far as we can tell.”
The researchers hope that their more detailed model for rate of infection spread and droplet spread will help inform public health policies at a more local level, and can be used in the future to better understand the role of environmental factors in virus spread.
They found that at 35C (95F) and 40 percent relative humidity, a droplet can travel about 8 feet. However, at 5C (41F) and 80 percent humidity, a droplet can travel up to 12 feet. The team also found that droplets in the range of 14-48 microns possess higher risk as they take longer to evaporate and travel greater distances. Smaller droplets, on the other hand, evaporate within a fraction of a second, while droplets larger than 100 microns quickly settle to the ground due to weight.
This is further evidence of the importance of wearing masks, which would trap particles in this critical range.
The team of engineers from the UC San Diego Jacobs School of Engineering, University of Toronto and Indian Institute of Science are all experts in the aerodynamics and physics of droplets for applications including propulsion systems, combustion or thermal sprays. They turned their attention and expertise to droplets released when people sneeze, cough or talk when it became clear that COVID-19 is spread through these respiratory droplets. They applied existing models for chemical reactions and physics principles to droplets of a salt water solution–saliva is high in sodium chloride–which they studied in an ultrasonic levitator to determine the size, spread, and lifespan of these particles in various environmental conditions.
Many current pandemic models use fitting parameters to be able to apply the data to an entire population. The new model aims to change that.
“Our model is completely based on “first principles” by connecting physical laws that are well understood, so there is next to no fitting involved,” said Swetaprovo Chaudhuri, professor at University of Toronto and a co-author. “Of course, we make idealized assumptions, and there are variabilities in some parameters, but as we improve each of the submodels with specific experiments and including the present best practices in epidemiology, maybe a first principles pandemic model with high predictive capability could be possible.”
There are limitations to this new model, but the team is already working to increase the model’s versatility.
“Our next step is to relax a few simplifications and to generalize the model by including different modes of transmission,” said Saptarshi Basu, professor at the Indian Institute of Science and a co-author. “A set of experiments are also underway to investigate the respiratory droplets that settle on commonly touched surfaces.”
In the wake of widespread social distancing and isolation due to the COVID-19 pandemic, people who have pets have gained a greater appreciation for the unconditional love and companionship they provide. However, for many older adults, especially those living with Alzheimer’s disease and/or related dementias (ADRD), caring for a pet is difficult. Moreover, because of the pandemic, people with ADRD and their caregivers remain alone for extended periods of time.
Researchers from Florida Atlantic University’s Christine E. Lynn College of Nursing provide the “purr-fect” solution to comfort and engage older adults with ADRD – interactive robotic cats. Designed to respond to motion, touch and sound, these interactive robotic pets offer an alternative to traditional pet therapy. Robotic cats and dogs are usually given to people with ADRD, but data has shown that using these pets to decrease social isolation for older adults is highly successful.
Older adults with COVID-19 who survive hospitalizations and return to their homes confront substantial health challenges and an unpredictable future. Early evidence suggests that complex and long-term physical, functional, cognitive, and emotional negative health consequences will be the norm for them. However, the trajectories of health care needs of older adults with COVID-19 in the weeks and months following hospital discharge have yet to be identified.
In an article in the Journal of Aging and Social Policy, three researchers from the University of Pennsylvania School of Nursing (Penn Nursing) explain how the core components of the Transitional Care Model, along with early findings regarding the unique concerns of those with COVID-19, suggest a path for immediate practice and policy responses to caring for this population as they transition from the hospital back to the community.
They worked in hospitals hundreds of miles from the epicenter of COVID-19. Their city of 24 million people locked down hard enough, and did enough testing, that it only had a few hundred cases of the disease.
But hundreds of young Chinese doctors in a new study still experienced a sharp drop in mood, a rise in depression and anxiety symptoms, and a doubling of their fear of workplace violence, in just the first month of the coronavirus pandemic.
As communities across the U.S. have struggled to cope with the effects of the COVID-19 pandemic, many have focused on the lack of widespread testing as a major barrier to safely reopening the country. As progress has been made on this front, concern has shifted to testing accuracy, predominantly with antibody tests, which are designed to identify prior infection.
But according to a new Dartmouth-led paper published in the New England Journal of Medicine, more emphasis should be placed on addressing the inaccuracy of diagnostic tests, which play a key role in containing the pandemic.
As if smoking weren’t bad enough for you, it seems the new coronavirus likes it, too.
The lungs of people who smoke may contain more of the receptors that the new coronavirus uses to invade cells. This could explain why people with the virus who also smoke appear to be particularly vulnerable to severe illness.
The majority of people who acquire SARS-CoV-2, the virus that causes COVID-19, experience mild-to-moderate symptoms and will fully recover without hospital treatment.
However, several studies suggest that people who smoke are significantly more likely than people who do not to develop a severe form of the illness.
For example, according to a recent study of COVID-19 cases in hospitals in mainland China, 11.8% of people who smoked had a nonsevere form of the disease, while 16.9% had severe disease.
To break into cells and start replicating itself, the virus latches onto a protein receptor called angiotensin-converting enzyme 2 (ACE2), which is present in the cells’ membranes.
Like the gift that keeps on giving, COVID-19 is the plague that keeps on taking. It turns out that the affliction can cause complications with other medical conditions.
COVID-19 can cause serious cardiovascular complications including heart failure, heart attacks and blood clots that can lead to strokes, emergency medicine doctors report in a new scientific paper. They also caution that COVID-19 treatments can interact with medicines used to manage patients’ existing cardiovascular conditions.
The new paper from UVA Health’s William Brady, MD, and colleagues aims to serve as a guide for emergency-medicine doctors treating patients who may have or are known to have COVID-19. The authors note that much attention has been paid to the pulmonary (breathing) complications of COVID-19, but less has been said about the cardiovascular complications that can lead to death or lasting impairment. Continue reading →
There are a plethora of masks around, homemade as well as store bought. The range of effectiveness is vast. The Journal of the American Medical Association (JAMA) suggests that face shields may be a worthwhile alternative.
Face shields come in various forms, but all provide a clear plastic barrier that covers the face. For optimal protection, the shield should extend below the chin anteriorly, to the ears laterally, and there should be no exposed gap between the forehead and the shield’s headpiece. Face shields require no special materials for fabrication and production lines can be repurposed fairly rapidly. Numerous companies, including Apple, Nike, GM, and John Deere, have all started producing face shields. These shields can be made from materials found in craft or office supply stores. Thus, availability of face shields is currently greater than that of medical masks.
Since the outbreak of the COVID-19 pandemic, N95 face masks have been in short supply. Health care workers, in particular, desperately need these masks to protect themselves from the respiratory droplets of infected patients. But because of the shortage, many have to wear the same mask repeatedly. Now, researchers reporting in ACS Nano, the American Chemical Society publication, have tested several methods for disinfecting N95 materials, finding that heating them preserves their filtration efficiency for 50 cycles of disinfection.
N95 masks contain a layer of “meltblown” polypropylene fibers that form a porous, breathable network. To help capture smaller particles that could slip through the holes, the fibers are electrostatically charged. The U.S. Centers for Disease Control and Prevention has recommended several methods for disinfecting N95 masks, such as heating, ultraviolet (UV) radiation and bleach treatment, but so far they have not been tested extensively, especially for multiple rounds of disinfection. Yi Cui and colleagues wanted to compare five of the methods that could reasonably be used within a hospital setting to see how mask materials hold up to repeated disinfections. Continue reading →
The coronavirus attacks us on a number of fronts, respiratory system big time. But, living in the shadow of the virus takes a toll on all of us whether we succumb to the disease or not. It has changed our daily lives in many stressful ways. The following is from Dr. Amit Sood , former internal medicine physician at Mayo Clinic. He was director of research in the Complementary and Integrative Medicine Program at Mayo Clinic in Rochester, Minnesota, and was chair of the Mind-Body Medicine Initiative at Mayo Clinic.